337 related articles for article (PubMed ID: 33713323)
21. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
22. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K; von der Schulenburg JG; Greiner W
Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
[TBL] [Abstract][Full Text] [Related]
23. A national survey of Iranian general population to estimate a value set for the EQ-5D-5L.
Afshari S; Daroudi R; Goudarzi R; Mahboub-Ahari A; Yaseri M; Sari AA; Ameri H; Bahariniya S; Oliaei-Manesh A; Kalavani K; Zare Z; Hasannezhad E; Mirzaei M; Amiri Z
Qual Life Res; 2023 Jul; 32(7):2079-2087. PubMed ID: 36897530
[TBL] [Abstract][Full Text] [Related]
24. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values.
Shah KK; Ramos-Goñi JM; Kreimeier S; Devlin NJ
Eur J Health Econ; 2020 Sep; 21(7):1091-1103. PubMed ID: 32506281
[TBL] [Abstract][Full Text] [Related]
25. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
[TBL] [Abstract][Full Text] [Related]
26. The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data.
Jensen CE; Sørensen SS; Gudex C; Jensen MB; Pedersen KM; Ehlers LH
Appl Health Econ Health Policy; 2021 Jul; 19(4):579-591. PubMed ID: 33527304
[TBL] [Abstract][Full Text] [Related]
27. EQ-5D-Y Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M;
Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
[TBL] [Abstract][Full Text] [Related]
28. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
29. Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off.
Paveliu MS; Olariu E; Caplescu R; Oluboyede Y; Niculescu-Aron IG; Ernu S; Vale L
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299864
[TBL] [Abstract][Full Text] [Related]
30. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
[TBL] [Abstract][Full Text] [Related]
31. An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D.
Feng Y; Herdman M; van Nooten F; Cleeland C; Parkin D; Ikeda S; Igarashi A; Devlin NJ
Qual Life Res; 2017 Aug; 26(8):2067-2078. PubMed ID: 28343350
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
[TBL] [Abstract][Full Text] [Related]
33. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy SA; Abbassi MM; Finch AP; Baines D; Farid SF
Pharmacoeconomics; 2021 May; 39(5):549-561. PubMed ID: 33709283
[TBL] [Abstract][Full Text] [Related]
34. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
[TBL] [Abstract][Full Text] [Related]
35. Measuring health-related quality of life in the general population and Roma communities in Romania: study protocol for two cross-sectional studies.
Olariu E; Paveliu MS; Baican E; Oluboyede Y; Vale L; Niculescu-Aron IG
BMJ Open; 2019 Aug; 9(8):e029067. PubMed ID: 31427330
[TBL] [Abstract][Full Text] [Related]
36. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
[TBL] [Abstract][Full Text] [Related]
37. Valuing health-related quality of life: An EQ-5D-5L value set for England.
Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
[TBL] [Abstract][Full Text] [Related]
38. International Valuation Protocol for the EQ-5D-Y-3L.
Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
[TBL] [Abstract][Full Text] [Related]
39. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
40. Study protocol for valuing EQ-5D-3L and EORTC-8D health states in a representative population sample in Sri Lanka.
Kularatna S; Whitty JA; Johnson NW; Scuffham PA
Health Qual Life Outcomes; 2013 Sep; 11():149. PubMed ID: 24070162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
